Companies / BOC Sciences / Ficlatuzumab
BOC Sciences

Ficlatuzumab | BOC Sciences

Ficlatuzumab is a humanized monoclonal antibody that binds to hepatocyte growth factor (HGF), resulting in inhibtion of c-Met signaling pathway. Ficlatuzumab has been approved for the treatment of head and neck cancer.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.